Orientador: Ana Carolina Gomes Jardim / Resumo: Nas últimas décadas, diversos vírus que tinham sua ocorrência limitada a pequenas regiões se espalharam pelo globo, causando epidemias e preocupação entre as autoridades de saúde. Apesar dos inúmeros avanços no tratamento das infecções virais, vários destes vírus ainda não possuem tratamento especifico e eficaz. Adicionalmente, a alta taxa de resistência e o surgimento de novas mutações, torna a busca por novos antivirais desafiadora e de extrema importância. Desta forma, o presente trabalho teve como objetivo investigar a atividade antiviral de compostos de origem natural ou sintética contra os vírus da Chikungunya (CHIKV) e Enterovirus A71 (EV-A71). Contra o CHIKV, 48.750 compostos sintéticos foram inicialmente avaliados in silico por docking molecular, dos quais 12 compostos demonstraram apresentar interação com a região de ligação a ADP-ribose do dominío macro da proteína viral não estrutural 3 (nsP3), e foram selecionados para ensaios in vitro. Ensaios de viabilidade celular foram realizados para determinar a máxima concentração não tóxica de cada composto, que foi utilizada nos ensaios anti-CHIKV em células de hepatocarcimona humano Huh-7, transfectadas com os replicons subgenômicos do CHIKV. Os resultados demonstraram que os compostos C5 e C13 na concentração de 20 µM inibiram 53 e 76% da replicação do CHIKV em células Huh-7, respectivamente. Contra o EV-A71, 6 proteínas isoladas da peçonha de serpentes foram testadas em concentrações não tóxicas em células Vero infect... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: In the last decades, several viruses that had their occurrence limited to small regions spread through the globe, causing epidemics and concern among health authorities. Despite the numerous advances in the treatment of viral infections, several of these viruses have no specific and effective treatment yet. In addition, the high rate of resistance and the emergence of new mutations, makes the search for new antivirals challenging and extremely important. The present work aimed to investigate the antiviral activity of compounds from natural or synthetic origin against Chikungunya virus (CHIKV) and Enterovirus A71 (EV-A71). Against CHIKV, 48,750 synthetic compounds were initially evaluated in silico by molecular docking, of which 12 compounds demonstrated to be interacting with the ADP-ribose binding region of viral non- structural protein 3 (nsP3) macro domain and were selected for in vitro assays. Cell viability assays were performed to determine the maximum non-toxic concentration of each compound and used in anti-CHIKV assays in human hepatocarcinoma cells (Huh-7) transiently transfected with the CHIKV subgenomics replicons. The results demonstrated that the C5 and C13 compounds at 20 µM inhibited 53 and 76% of CHIKV replication in Huh-7 cells, respectively. Against EV-A71, 6 proteins isolated from snake venom were tested at non-toxic concentrations in infected Vero cells, and the virucidal, protective and anti-EV-A71 replication activity was evaluated. From the tested toxi... (Complete abstract click electronic access below) / Doutor

No description available.

La maladie pied-main-bouche (PMB) et l’herpangine sont deux maladies pédiatriques bénignes causées par les entérovirus (EV), en particulier les sérotypes de l’espèce A (EV-A). Le sérotype EV-A71 fait l’objet d’une surveillance dans les pays du Sud Est de l’Asie car il est associé à des atteintes neurologiques sévères chez les très jeunes enfants, parfois mortelles (défaillance cardio-pulmonaire). Les infections causées par les autres EV-A tel que le coxsackievirus A16 (CV-A16) provoquent rarement des atteintes sévères. En Europe, les cas de maladie PMB causés par l’EV-A71 ne font pas l’objet d’une déclaration obligatoire, car ce virus ne cause pas d’épidémies de grande ampleur. L’objectif général de la thèse était d’étudier l’épidémiologie des EV-A en Europe et nous avons utilisé une approche phylogénétique bayésienne pour analyser un échantillon de 500 souches. Nous montrons la circulation discontinue de l’EV-A71 de deux populations virales principales (sous génogroupes C1 et C2), ce qui explique la rareté des épidémies en Europe. L’épidémiologie de ce virus est aussi caractérisée par des transports de souches entre les pays Européens et sporadiquement entre l’Europe et l’Asie (sous génogroupes B5 et C4). La recombinaison génétique intertypique survient rarement parmi les populations d’EV-A71 en circulation et ne contribue pas significativement à leur diversité génétique. Cependant, ce mécanisme génétique est relié à l’émergence d’un sous génogroupe CV-A16 qui circule en France depuis 2011. Comparés à l’EV-A71, les sérotypes CV-A2, CV-A4, CV-A6 sont plus fréquemment sujets à des événements de recombinaison intertypiques. L’analyse de la sélection à l’échelle moléculaire indique que la fixation des mutations dans les protéines de capside de l’EV-A71 est lente, probablement à cause des contraintes structurales et fonctionnelles. La surveillance des infections à EV-A71 en Europe devrait être renforcée à cause de la neurovirulence de ce virus, de l’introduction récente et répétée de souches variantes « asiatiques » et de l’existence d’une grande diversité de génogroupes en Afrique et en Inde encore peu explorée. / Hand-Foot and Mouth Disease (HFMD) and Herpangina are two benign pediatric diseases caused by Enteroviruses (EV), especially enterovirus A species serotypes (EV-A). Infections caused by the EV-A71 serotype are monitored in countries of South East Asia because they are associated with severe neurological symptoms in young children and may be fatal (cardiopulmonary failure). Infections caused by the other EV-A serotypes, e.g. coxsackievirus A16 (CV-A16), rarely induce severe symptoms. In Europe, EV-A71 HFMD cases are not notifiable because this virus does not cause large-scale epidemics. The overall objective of this thesis was to study the EV-A epidemiology in Europe and we used a Bayesian phylogenetic approach to analyze 500 viral strains. We show a discontinued circulation of two EV-A71 populations (C1 and C2 subgenogroups), which explains the rare outbreaks in Europe. The epidemiology of this virus is characterized by transportation events of viral strains between European countries and sporadically between Europe and Asia (C4 and B5 subgenogroups). Intertypic genetic recombination occur rarely among circulating EV-A71 populations and does not contribute significantly to their genetic diversity. We found that genetic mechanism was related to the emergence of a new CV-A16 subgenogroup, which is circulating in France since 2011. In comparison with EV-A71, a number of serotypes (CV-A2, CV-A4, and CV-A6) are more frequently involved in intertypic recombination events. The structural and functional constraints are possible factors involved in the slow mutation fixation in the EV-A71 capsid proteins as determined by analyses of molecular selection. Neurovirulence, the recent and repeated introductions of variants “Asian” strains, and the diversity of genogroups in Africa and India call for strengthened surveillance of EV-A71 infections among European countries.